(VCBeat) July. 26, 2021 -- ZSHK Laboratories Limited ("ZSHK Lab") announced the completion of a ¥100 million Series A round of financing, led by Qiming Venture Partners, with participation from Jishi Capital. Proceeds from this round will mainly be used for laboratory construction, talent recruitment and business expansion.
According to Dr. Li Ming, founder and CEO of ZSHK Lab, ZSHK Lab was founded by the core team of the Safety Evaluation Center of Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS). Its main business was pre-clinical research evaluation services for biomedicine and medical devices. The company is a one-stop R&D service platform for pharmacodynamics, pharmacokinetics and safety evaluation, with headquarters in Hong Kong, China.
ZSHK Lab has set up independent laboratories in Hong Kong Science and Technology Park, Pingshan District in Shenzhen, Guangdong Province, and Suzhou Industrial Park in Jiangsu Province. At present, the pre-clinical drug evaluation service laboratory in Suzhou Industrial Park has been put into operation, the laboratory in Hong Kong Science Park (the only pre-clinical drug safety evaluation institution in Hong Kong), and the new drug and medical device evaluation laboratory in Pingshan, Shenzhen will be officially opened in the second half of this year.
About Qiming Venture Partners
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston, and San Francisco Bay Area. Currently, Qiming Venture Partners manages seven US Dollar funds and five RMB funds with over US$4 billion assets under management. Qiming Venture Partners invests in information technology, new consumer business patterns, and the healthcare sector.
About Jishi Capital
Jishi Capital is a new cutting-edge medical fund established in 2020, focusing on investment in innovative medical devices, biomedical, and related technologies. The team is jointly established by senior professionals in the medical field and investment field. It takes promoting the development of the healthcare industry as its own responsibility, and is committed to finding innovative medical products and technologies worldwide to help develop and launch products in the current Chinese market.